Steven Holtzman was Appointed as President and Chief Executive Officer at Decibel Therapeutics

Date of management change: July 15, 2016 

What Happened?

Boston, MA-based Decibel-Therapeutics Appointed Steven Holtzman as President and Chief Executive Officer

 

About the Company

Decibel Therapeutics is a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, one of the largest areas of unmet need in medicine. Decibel has built a proprietary platform that integrates single-cell genomics and bioinformatic analyses, precision gene therapy technologies and expertise in inner ear biology. Decibel is leveraging its platform to advance gene therapies designed to selectively replace genes for the treatment of congenital, monogenic hearing loss and to regenerate inner ear hair cells for the treatment of acquired hearing and balance disorders. Decibel`s pipeline, including its lead gene therapy program, DB-OTO, to treat congenital, monogenic hearing loss, is designed to deliver on our vision of a world in which the privileges of hearing and balance are available to all.

 

About the Person

Steven  Holtzman is President and Chief Executive Officer at Decibel Therapeutics. Previously, Steven  held various senior HR leadership roles in the industry.

 

Info Source

News

 
 

Other IT executives who recently changed jobs as well: Strack Karen, Ganov Ilya, Ulrich Helen, Kedzior Brian, Batiste Monica, Voisinet Bob, Pazzanese John, Bonsera Cami, McIntosh Jim, Byrne Ryan, Potter Iina

You can find the full directory of IT executives here.

How would you like to connect with 15,000+ IT executives in charge of $ millions in IT budgets? Find details here.